Sterling Capital Management LLC Has $7.83 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Sterling Capital Management LLC raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 19.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,850 shares of the biotechnology company's stock after purchasing an additional 9,065 shares during the quarter. Sterling Capital Management LLC owned approximately 0.09% of Ascendis Pharma A/S worth $7,827,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FIL Ltd lifted its stake in shares of Ascendis Pharma A/S by 13.9% during the 4th quarter. FIL Ltd now owns 729,275 shares of the biotechnology company's stock worth $100,399,000 after buying an additional 89,016 shares during the last quarter. American Century Companies Inc. raised its holdings in Ascendis Pharma A/S by 17.5% in the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock valued at $56,072,000 after acquiring an additional 60,548 shares during the period. Artisan Partners Limited Partnership lifted its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after acquiring an additional 39,309 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Ascendis Pharma A/S by 94.4% during the fourth quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock worth $10,659,000 after acquiring an additional 37,593 shares during the period. Finally, abrdn plc grew its position in shares of Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after purchasing an additional 28,967 shares during the last quarter.

Remove Ads

Ascendis Pharma A/S Stock Down 1.0 %

Shares of NASDAQ ASND traded down $1.58 during trading on Tuesday, reaching $153.92. The company had a trading volume of 255,010 shares, compared to its average volume of 478,466. The stock has a market cap of $9.38 billion, a P/E ratio of -21.68 and a beta of 0.54. The company's fifty day moving average price is $149.43 and its 200-day moving average price is $137.82. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

ASND has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Cantor Fitzgerald raised their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research report on Tuesday, February 18th. UBS Group assumed coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target on the stock. Finally, Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.